Form 4: Aadi Bioscience Executive Chairman Neil Desai Sells Shares

Neil Desai, Executive Chairman of Aadi Bioscience, sold shares of common stock between August 1 and August 5, 2024, according to a Form 4 filing with the SEC.

Summary

• Neil Desai, the Executive Chairman of Aadi Bioscience, sold shares of the company's common stock.
• The sales occurred on August 1, August 2, and August 5, 2024.
• A total of 15,415 shares were sold on August 1 at a weighted average price of $1.4956.
• On August 2, 18,933 shares were sold at a weighted average price of $1.4105.
• 5,652 shares were sold on August 5 at a weighted average price of $1.3437.
• The sales were executed under a Rule 10b5-1 trading plan.
• Following these transactions, Desai indirectly owns 1,211,543 shares through the Anishka Family Trust and 639,698 shares through the Anishka Irrevocable 2016 Trust.

Sentiment

Score: 4

Explanation: Executive selling shares can create negative sentiment, but the existence of a 10b5-1 plan mitigates some concern.

Negatives

• The Executive Chairman selling shares could be interpreted negatively by the market.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is not always the case.

Industry Context

Insider sales are a common occurrence in publicly traded companies and are often part of executives' personal financial planning. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.

Stakeholder Impact

• Shareholders may react to the news of the Executive Chairman selling shares.
• The impact on other stakeholders is likely minimal.

Key Dates